X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213731
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213782
https://www.otsuka.co.jp/en/company/newsreleases/2023/20231031_1.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213758
https://endpts.com/fda-adcomm-votes-in-favor-of-first-drug-for-agitation-associated-with-alzheimers-dementia/
https://www.fiercepharma.com/pharma/otsuka-lundbeck-head-key-fda-hearing-agency-support-their-rexulti-application
https://endpts.com/ahead-of-adcomm-fda-backs-rexulti-for-first-approval-for-agitation-associated-with-alzheimers-dementia/
https://endpts.com/otsuka-lundbeck-eye-alzheimers-indication-in-fda-adcomm-for-rexulti-label-expansion/
https://health.economictimes.indiatimes.com/news/pharma/usfda-approves-lupins-brexpiprazole-tablets-for-schizophrenia-and-depression/98894725
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-to-market-generic-antidepressant-drug/articleshow/98514180.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213718
https://www.otsuka.co.jp/en/company/newsreleases/2023/20230130_1.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213740
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213660
https://endpts.com/fda-accepts-one-delays-another-data-deals-and-dollars-for-slate-of-biotechs/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213570
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213477
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213692
https://www.otsuka.co.jp/en/company/newsreleases/2022/20220805_1.html
https://www.fiercepharma.com/pharma/trial-results-show-lundbeck-and-otsukas-brexpiprazole-can-reduce-agitation-alzheimers
https://endpts.com/otsuka-puts-nearly-1-billion-on-the-line-for-four-neuropsychiatric-candidates-from-sunovion/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213782
https://www.expresspharma.in/zydus-cadila-receives-tentative-approval-from-us-fda-for-brexpiprazole-tablets/
https://www.thepharmaletter.com/in-brief/brief-two-japanese-drug-approvals-for-otsuka-busulfex-and-rexulti?__cf_chl_jschl_tk__=pmd_.W9CAGWFIxVQa8SGiCBZJJxulaUx0plWDleiTL7DZWU-1629974977-0-gqNtZGzNAmWjcnBszQil
https://news.cision.com/h--lundbeck-a-s/r/the-danish-business-authority--erhvervsstyrelsen--requires-lundbeck-to-conduct-a-new-impairment-test,c3245409
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-rexulti-205422-brexpiprazoletablets-025-mg-05-mg-1-mg-2-mg-3-mg-and-4-mg-1569470931.pdf
http://www.pmlive.com/pharma_news/lundbecks_key_products_shine_in_q2_but_problems_remain_1297435
https://www.biospace.com/article/lundbeck-and-otsuko-s-antipsychotic-drug-rexulti-fails-two-bipolar-phase-iii-trials/
https://www.fiercebiotech.com/biotech/lundbeck-and-otuska-s-brexpiprazole-hits-mark-ptsd-trial
https://endpts.com/lundbecks-dunsire-has-something-to-cheer-as-rexulti-combo-shows-promise-in-ptsd/
https://www.ema.europa.eu/documents/product-information/rxuti-epar-product-information_en.pdf
https://www.api.polpharma.com/articles/brexpiprazole-another-successful-project-in-api-r-d
https://www.fiercepharma.com/marketing/abbvie-humira-pfizer-lyrica-steady-at-top-february-ad-chart-but-see-new-entrant-ibrance
http://www.fiercepharma.com/marketing/otsuka-and-lundbeck-revives-rexulti-mask-campaign-as-u-s-uptake-drug-soars
http://www.businesswire.com/news/home/20170217005717/en/Health-Canada-Approves-Otsuka-Lundbecks-REXULTI%E2%84%A2-brexpiprazole/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://www.pharmacompass.com/pdf/news/otsuka-pharms-brexpiprazole-approved-in-us-1474960241.pdf
Market Place
Share 
